Adeno-associated viral (AAV) vectors are a leading platform for gene therapy development, with approved therapies including Luxturna® (indicated for RPE65-mediated inherited retinal dystrophy) and Zolgensma® (indicated for spinal muscular atrophy) demonstrating the clinical utility of AAV-mediated gene delivery. Beyond approved gene replacement therapies, next-generation gene-silencing candidates are advancing rapidly. uniQure’s AMT-130 (ifezuntirgene inilparvovec), administered via a one-time stereotactic neurosurgical procedure directly into the striatum, reported a 75% slowing of disease progression at 36 months in Phase 1/2 trials compared to matched external controls1. Despite advances in vector engineering, translating preclinical findings into clinical success for complex disorders, such as inherited retinal dystrophies, spinal muscular atrophy, Huntington’s disease and hemophilia, remains challenging.
Traditional cell lines and animal models remain important components of AAV development, while physiologically relevant human models can provide complementary insights into disease biology and therapeutic activity. Human iPSC-derived systems are increasingly being used to evaluate AAV performance in disease-relevant cell types²,3.
Human iPSC-derived models support AAV evaluation
Successful AAV development requires evidence of efficient transduction, robust transgene expression, target engagement, therapeutic activity and safety profile in relevant human cell types. For neurodegenerative and retinal diseases, a key challenge is evaluating these endpoints in models that capture disease-specific phenotypes and clinically relevant cellular responses.
Human iPSC-derived models can complement existing preclinical workflows by providing access to disease-relevant cell types in a controlled experimental setting. Unaffected donor-derived models support vector characterization, transduction studies, assay optimization, and preliminary assessment of vector-related toxicity, while patient-derived disease models can enable assessment of therapeutic activity and disease-specific responses.
Advanced model systems, including patient-derived models, co-cultures, and organoids, are increasingly being incorporated into AAV workflows to generate more biologically relevant preclinical data. These approaches support evaluation of functional endpoints and patient-specific responses, helping developers assess both vector performance and biological activity before clinical development²,3.
Retinal organoids as a platform for AAV characterization
Inherited retinal diseases are a major focus of AAV-mediated gene therapy development. Human iPSC-derived retinal organoids provide a multicellular human retinal model that can be used to assess vector tropism and transgene expression in retinal cell populations.
In a study conducted by McClements ME and colleagues in collaboration with the University of Oxford and Axol Bioscience (former Newcells Biotech), human iPSC-derived retinal organoids were used to compare the performance of AAV5, AAV2 7m8, AAV2 quad mutant, AAV2 Y444F, and AAV8 Y733F vectors. Using green fluorescent protein (GFP) reporter constructs driven by the ubiquitous CAG promoter, the authors observed differences in transduction efficiency between vectors. The AAV2 quad mutant and AAV2 7m8 vectors achieved the highest proportion of GFP-positive cells within retinal organoids, transducing approximately 19.4% and 16.4% of cells, respectively. Reporter gene expression was detected as early as 5 days after transduction and increased over time, demonstrating sustained transgene expression within the retinal organoids.








